Myriad Genetics (MYGN) Change in Receivables (2009 - 2026)

Myriad Genetics has disclosed Change in Receivables across 18 years of filings, most recently posting $8.7 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 1187.5% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $3.3 million (down 17.5% YoY), while the FY2025 annual figure was -$6.2 million, down 171.26% from the prior year.
• Change in Receivables advanced to $8.7 million in Q1 2026, from -$2.6 million in the prior quarter.
• Over the last five years, Change in Receivables for MYGN reached as high as $17.5 million in Q1 2023 and fell as low as -$19.0 million in Q3 2025.
• The 5-year median for Change in Receivables is $600000.0 (2024), against an average of $2.0 million.
• Annual changes were most pronounced in 2022 — Change in Receivables plunged 1120.0% — and 2025, when it jumped 2600.0%.
• A 5-year view of Change in Receivables shows it stood at -$2.5 million in 2022, then jumped by 52.0% to -$1.2 million in 2023, then tumbled by 233.33% to -$4.0 million in 2024, then soared by 35.0% to -$2.6 million in 2025, then surged by 434.62% to $8.7 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $8.7 million, -$2.6 million, and -$19.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.